Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794847 | 0.90 | MAPT (0.51) | ALDH1A1MAPTMEN1TSHRKMT2A | |
| SCHEMBL21411461 | 0.85 | ALDH1A1 (0.62) | ALDH1A1MAPTGAAHTTCYP3A4 | |
| SCHEMBL14081979 | 0.81 | MAPT (0.51) | ALDH1A1MAPTMEN1TSHRKMT2A | |
| SCHEMBL3989430 | 0.80 | GAA (0.34) | ALDH1A1MAPTMEN1TSHRKMT2A | |
| SCHEMBL14081980 | 0.79 | MAPT (0.50) | ALDH1A1MAPTMEN1TSHRKMT2A | |
| SCHEMBL28501406 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTGAAHTTCYP3A4 | |
| SCHEMBL28250542 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL15398578 | 0.79 | MEN1 (0.35) | ALDH1A1MAPTMEN1TSHRKMT2A | |
| SCHEMBL4493181 | 0.79 | HRH3 (0.54) | ALDH1A1MAPTMEN1TSHRKMT2A | |
| SCHEMBL4499465 | 0.79 | HRH3 (0.54) | ALDH1A1MAPTMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423454-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-09 | — | — | EP | disclosed |
| US-7485647-B2 | 2-aminoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MSD K.K. (JP) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MCHR2, MC2R, MCHR1 | ALDH1A1 1932/4885MAPT 3412/4885MEN1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.